Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome

Acta Neurol Scand. 2015 Feb;131(2):140-3. doi: 10.1111/ane.12357.

Abstract

Background: Sjogren syndrome (SS) is a common autoimmune disease characterized by lymphocytic infiltration of the exocrine glands with neurological involvement in about 20% of patients. The neurological manifestations in the central nervous system CNS may vary and include a multiple sclerosis (MS)-like disease, and the treatments with immunosuppressive drugs have been undertaken.

Case presentation: We describe a case of 40-year-old woman with clinical and instrumental evidence of an MS characterized by numerous relapses and demyelinating lesions prevailing in the infratentorial and spinal cord. Immunological analysis showed biological data that were consistent with an SS. The treatment with fingolimod showed not only an optimal response to the demyelinating events but also biological parameters.

Conclusion: These data allow us to hypothesize possible combined efficacy of treatment with fingolimod in SS associated with definite MS.

Keywords: Sjogren syndrome; fingolimod; multiple sclerosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Fingolimod Hydrochloride
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / pathology
  • Propylene Glycols / therapeutic use*
  • Sjogren's Syndrome / complications*
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / pathology
  • Sphingosine / analogs & derivatives*
  • Sphingosine / therapeutic use

Substances

  • Immunosuppressive Agents
  • Propylene Glycols
  • Fingolimod Hydrochloride
  • Sphingosine